Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Caraco Pharmaceutical Laboratories Ltd.

Latest From Caraco Pharmaceutical Laboratories Ltd.

Sun’s Tildrakizumab Shines In Pivotal Psoriasis Trials

Sun Pharmaceutical, the world’s fifth-largest specialty generic company, has reported positive results from two pivotal Phase III clinical trials for its psoriasis candidate tildrakizumab, showing that the targeted biologic therapy delivers “significantly improved” skin clearance. While it will face rising competition, some analysts are predicting strong sales

Clinical Trials Dermatology

Sun Profit Dives On Ranbaxy Merger Costs

Sun Pharmaceutical Industries, India’s biggest drug maker by sales, has reported a 30% drop in quarterly net profit from a year earlier, undershooting analysts’ expectations for a third straight trimester and reflecting in part the costs of digesting its merger with Ranbaxy.

BioPharmaceutical India

Sun Profit Dives On Ranbaxy Integration Costs

Sun Pharmaceutical Industries, India’s biggest drug maker, has announced a 60% slump in quarterly net profit from a year earlier, hit by one-off charges as it integrates troubled former rival Ranbaxy, acquired from Japanese owners Daiichi Sankyo earlier this year. But the generics giant says the “short-term pain” will result in long-term gain.

BioPharmaceutical India

FDA ‘Monster’ Patent Reg: Brands, Generics Each Want More Options To Pick Fights

PhRMA is concerned about the agency giving deference to generic sponsors in patent use code disputes, while GPhA wants a mechanism to challenge refuse-to-receive letters.

BioPharmaceutical United States
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • OTC, Consumer